BioWorld Asia

April 6, 2005

PharmaMar's Yondelis Phase III Trial Started In Ovarian Cancer

Taking aim at relapsed ovarian cancer patients considered incurable, Madrid, Spain-based PharmaMar SA is starting a Phase III trial with Yondelis (trabectedin), a compound first isolated from marine tunicates. (BioWorld International) Read More

Rosetta Genomics Brings In $4M For Preclinical Studies

Identifying Pre-Eclampsia Gene Could Bring Diagnostic Testing

Nautilus Biotech Gets EUR7.25M In Third Round Of Financing

Ark, Boehringer Ingelheim Form Collaboration Over IP

Syngenta Slip-Up Causes Red Faces Across European Union

Israeli Chief Scientist Designates Biotech, Nanotech High Priorities

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...